Invited discussant abstracts 1222O and 1223O
| Date | 27 September 2014 |
| Event | ESMO 2014 |
| Session | NSCLC, metastatic 1 |
| Topics | Cytotoxic agents Non-small-cell lung cancer Therapy Biological therapy |
| Presenter | Pasi Janne |
| Authors |
P.A. Janne
|
View the abstracts discussed:
- A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8)
- ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC